Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Boehringer Ingelheim
McKinsey
Johnson and Johnson
Baxter

Last Updated: January 21, 2020

DrugPatentWatch Database Preview

VIRAZOLE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Virazole patents expire, and when can generic versions of Virazole launch?

Virazole is a drug marketed by Valeant Pharm Intl and is included in one NDA.

The generic ingredient in VIRAZOLE is ribavirin. There are fifteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ribavirin profile page.

US ANDA Litigation and Generic Entry Outlook for Virazole

  Start Trial

A generic version of VIRAZOLE was approved as ribavirin by TEVA on January 21st, 2020.

Drug patent expirations by year for VIRAZOLE
Drug Prices for VIRAZOLE

See drug prices for VIRAZOLE

Recent Clinical Trials for VIRAZOLE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Weill Medical College of Cornell UniversityEarly Phase 1

See all VIRAZOLE clinical trials

Pharmacology for VIRAZOLE
Synonyms for VIRAZOLE
1-?-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboxamide
1-(beta -D-ribofuranosyl)-1,2,4-triazole-3-carboxamide
1-(beta-D-Ribofuranosyl)-1,2,4-triazole-3-carboxamide
1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,2,4-triazole-3-carboxamide
1-|A-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-Ribofuranosyl-1,2,4-triazole-3-carboamide
1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-
1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-
36791-04-5
437710-49-1
49717AWG6K
4pb1
66510-90-5
791R045
AB00430481
AB00430481_17
AB00430481_18
AB00430481-15
AB00430481-16
AB0068936
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AJ-24715
AK-49185
AKOS001715163
API0004062
AS-34178
AX8005387
BB_NC-00567
BCP0726000138
BDBM50154375
BIB6306
BPBio1_001195
BR-49185
BRD-K60369935-001-02-7
BRD-K60369935-001-18-3
BRN 0892462
BSPBio_001085
BSPBio_003352
C-14783
C-Virin
CAS-36791-04-5
CC-34249
CCG-38985
CHEBI:63580
CHEMBL1643
cid_37542
Copegus
Copegus (TN)
Cotronak
CPD000058315
CS-2540
CTK7J7594
D00423
DB00811
DivK1c_000782
DRG-0028
Drug: Ribavirin
DSSTox_CID_3557
DSSTox_GSID_23557
DSSTox_RID_77081
DTXSID8023557
EN300-59237
EU-0101063
FT-0082885
FT-0630597
FT-0649908
GS-3572
GTPL6842
HMS2090L15
HMS2094O09
HMS2098G07
HMS2232P07
HMS3263E08
HMS3715G07
HMS502H04
HSDB 6513
HY-B0434
ICN-1229
IDI1_000782
IWUCXVSUMQZMFG-AFCXAGJDSA-N
J10190
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
Lopac0_001063
LP01063
LS-1241
M-7546
MCULE-9495128592
MFCD00058564
MLS000028486
MLS002222317
MolPort-002-507-104
NCGC00015904-02
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NCGC00090726-08
NCGC00090726-09
NCGC00090726-12
NCGC00258520-01
NCGC00261748-01
NINDS_000782
NSC 163039
NSC-758650
NSC163039
NSC758650
Pharmakon1600-01503938
Prestwick3_000993
PubChem14187
R 9644
R-964
R0077
Ravanex
RBV
Rebetol
Rebetol (TN)
Rebetron
Rebretron
RG-964
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
ribavirin
Ribavirin (Copegus)
Ribavirin (JP17/USP/INN)
Ribavirin [USAN:INN]
Ribavirin [USAN:USP:INN:BAN]
Ribavirin Capsules
Ribavirin, 98%
Ribavirin, antiviral
Ribavirin, British Pharmacopoeia (BP) Reference Standard
Ribavirin, European Pharmacopoeia (EP) Reference Standard
Ribavirin, Pharmaceutical Secondary Standard; Certified Reference Material
Ribavirin, United States Pharmacopeia (USP) Reference Standard
Ribavirin,(S)
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirine;
Ribavirinum
Ribavirinum [INN-Latin]
ribofluranosyl carboxamide
Ribovirin
Ro 20-9963/000
Ro-20-9963
RTC
RTCA
s2504
SAM002548967
SBI-0051033.P003
SC-12159
SCH 18908
SCHEMBL3727
SMP1_000261
SMR000058315
Spectrum_001826
SPECTRUM1503938
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
SR-01000076112
SR-01000076112-11
SR-01000076112-2
SR-01000076112-3
SR-01000076112-4
SR-01000721904
SR-01000721904-2
ST2413783
Tox21_110259
Tox21_110259_1
Tox21_200967
Tox21_501063
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Z1522567185
ZB015662
ZINC1035331
Paragraph IV (Patent) Challenges for VIRAZOLE
Tradename Dosage Ingredient NDA Submissiondate
VIRAZOLE FOR SOLUTION;INHALATION ribavirin 018859 2014-05-22

US Patents and Regulatory Information for VIRAZOLE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl VIRAZOLE ribavirin FOR SOLUTION;INHALATION 018859-001 Dec 31, 1985 AN RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIRAZOLE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl VIRAZOLE ribavirin FOR SOLUTION;INHALATION 018859-001 Dec 31, 1985   Start Trial   Start Trial
Valeant Pharm Intl VIRAZOLE ribavirin FOR SOLUTION;INHALATION 018859-001 Dec 31, 1985   Start Trial   Start Trial
Valeant Pharm Intl VIRAZOLE ribavirin FOR SOLUTION;INHALATION 018859-001 Dec 31, 1985   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Colorcon
Medtronic
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.